Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

6.35EUR
11:40am BST
Change (% chg)

€-0.01 (-0.24%)
Prev Close
€6.36
Open
€6.37
Day's High
€6.39
Day's Low
€6.29
Volume
84,801
Avg. Vol
310,260
52-wk High
€12.89
52-wk Low
€4.33

Chart for

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.11
Market Cap(Mil.): €603.39
Shares Outstanding(Mil.): 57.36
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.14 -- --
ROI: -4.04 1.58 14.38
ROE: -10.93 2.41 16.07

BRIEF-Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN

* PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN

17 Apr 2018

BRIEF-Reg-Innate Pharma Aacr 2018, New Preclinical Data Further Support Ongoing Programs

* REG-INNATE PHARMA : AACR 2018, NEW PRECLINICAL DATA FURTHER SUPPORT ONGOING PROGRAMS Source text for Eikon: Further company coverage:

17 Apr 2018

BRIEF-Innate Pharma Announces Its Partner Medimmune Expands Colorectal Cancer Patient Cohort In A Phase I Trial

* INNATE PHARMA SA - PARTNER MEDIMMUNE EXPANDS COLORECTAL CANCER PATIENT COHORT IN ONGOING PHASE I TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI® (DURVALUMAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 Mar 2018

BRIEF-Innate Pharma Expands mCRC Cohort In Phase I Trial Evaluating Monalizumab With Imfinzi

* REG-INNATE PHARMA : EXPANSION OF MCRC COHORT IN PHASE I TRIAL EVALUATING MONALIZUMAB WITH IMFINZI

23 Mar 2018

BRIEF-Innate Pharma FY Net Results Swings To Loss Of 48.4‍​ Million Euros

* FY REVENUE AND OTHER INCOME EUR 44.0‍​ MILLION VERSUS EUR 65.7 MILLION YEAR AGO

08 Mar 2018

BRIEF-Innate Pharma Appoints Jean-Yves Blay To Its Supervisory Board

* INNATE PHARMA SA - JEAN-YVES BLAY APPOINTED TO INNATE PHARMA SUPERVISORY BOARD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

31 Jan 2018

BRIEF-Innate Pharma And Medimmune Enter Clinical Trial Collaboration

* INNATE PHARMA AND MEDIMMUNE ENTER CLINICAL TRIAL COLLABORATION

30 Jan 2018

BRIEF-Eric Vivier Joins Innate Pharma As Chief Scientific Officer

* REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Jan 2018

BRIEF-Innate Pharma provides an update on lirilumab

* ‍LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS

22 Nov 2017

BRIEF-Innate Pharma Q3 revenue up at 12.4 million euros

* Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO

15 Nov 2017

Earnings vs. Estimates